Q32 Bio reports Part B data for bempikibart in alopecia areata at EADV 2026
The company said 36-week and off-drug follow-up results support moving bempikibart into a registration-directed program targeted for the first half of 2027.
SEC filing
Latest
5 stories
Yesterday
Wednesday, August 5
Q32 Bio posts positive bempikibart Phase 2a data, plans registration study for 2027
The company reported 36-week SIGNAL-AA Part B results in alopecia areata and said cash plus a $200 million offering should fund operations through Phase 3 topline data.
SEC filing
Wednesday, July 15
Q32 Bio prices public offering, expects about $187.6 million in net proceeds
The company signed an underwriting agreement on July 14, 2026 for shares and pre-funded warrants, with closing expected July 16, 2026.
SEC filing
Q32 Bio prices $200 million stock offering, cites SIGNAL-AA Part B data
The company priced 6,027,399 shares plus pre-funded warrants at $18.25 per share, alongside 36-week topline alopecia areata results from bempikibart.
SEC filing (2)
Monday, July 13
Q32 Bio reports positive Phase 2a bempikibart results in alopecia areata
Part B of the SIGNAL-AA trial hit its primary endpoint with a 35.3% mean SALT score reduction, and Q32 disclosed it paid off its SVB loan.
SEC filing (2)